This position, successfully executed, will lend some visibility, understanding and credibilty to RVX.

The challenge now is to get funding and at least start the Covid trial.

I hope there is now a ship full of gold sailing back from North West Africa to Calgary hopefully to arrive soon.

The most fundamental issue, consistent over the years, is the inability to fund their trials.

1. SUSTAIN - only 126 patients but it did show improvement in HDL-c and APOA-l.
2. ASSURE - short trial of 26 weeks and small sample of 323 patients. Failed to meet the primary end point of plaque regression but other important findings were highly significant and promising. Futility analysis not funded.
3. BETon MACE - Failed to meet primary endpoit of 3 point MACE reduction. Post hoc analysis has shown many promising results. Futility analysis not funded. Had the funds been available for the futility analysis apabetalone may be close to certification at this stage.
4. BOM2 - Don told us a BP recommended a 5 year trial but RVX decided they can do it in 3 years with a much smaller sample size. So "we" (RVX) is smarter than the BP that has probably been through this multiple times before???
5. Then think about all of the other trials that are not being funded like HIV, etc. If any one of these trials succeeded apabetalone may be approved for that indication and that could lead to off label use.

All of the evidence and even the vote of confidence by the FDA giving apabetalone BTD status suggests that apabetalone is probably going to be a blockbuster drug that should be on the market helping patients ASAP. Yet here we have a CEO flying to Morocco begging for funding. This is absolutely absurd and incomprehensible from my perspective. I realize others may disagree and that is fine.

I think the fundamental issue is either lack of the required skill set or it is an attitude issue. This drug deserves big thinking in both the science and financing.

GLTA 

Toinv